A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation

Transplantation

Volumn 61, Issue 2, 1996, Pages 261-273

  Gruessner, Rainer W G ^a,b   Burke, George W ^a   Stratta, Robert ^a   Sollinger, Hans ^a   Benedetti, Enrico ^a   Marsh, Christopher ^a   Stock, Peter ^a   Boudreaux, J Philip ^a   Martin, Maureen ^a   Drangstveit, Mary Beth ^a   Sutherland, David E R ^a   Gruessner, Angelika ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADULT; AGED; ALLOGRAFT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT FAILURE;

ADOLESCENT; ADULT; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; SURVIVAL ANALYSIS; TACROLIMUS;

EID: 9044243407     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199601270-00018     Document Type: Article

References (38)

1. Klintmalm G. The U. S. Multi-center FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after liver transplantation. N Engl J Med 1994; 331: 1110.
2. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995; 59: 485.
3. Armitage JM, Kornos RL, Fung JJ, Starzl TE. The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc 1991; 23: 3054.
4. Griffith BP, Bando K, Hardesty RL, et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation 1994; 57: 848.
5. Todo S, Tzakis A, Reyes J, et al. Small intestinal transplantation in humans with or without the colon. Transplantation 1994; 57: 840.
6. Ricordi C, Tzakis A, Carroll P, et al. Human islet allotransplantation under FK506. Transplant Proc 1991; 23: 3207.
7. Scantlebury R, Shapiro R, Fung J, et al. New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 1991; 23: 3169.
8. Teraoka S, Babazono T, Koike T, et al. Effect of rescue therapy using FK 506 on relapsing rejection after combined pancreas and kidney transplantation. Transplant Proc 1995; 27: 1335.
9. Shaffer D, Simpson MA, Conway P, Madras PN, Monaco AP. Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). Transplantation 1995; 59: 1063.
10. Gruessner A, Sutherland DER. Pancreas transplant results in the United Network for Organ Sharing (UNOS) United States of America (USA) Registry compared with non-USA data in the International Registry. In: Terasaki PI, Cecka JM, eds. Clinical Transplants 1994, Los Angeles, UCLA Tissue Typing Laboratory, 1995: 47.
11. Gruessner A. Results of the International Pancreas Transplant Registry - an update, 1994.
12. Gruessner RWG, Dunn DL, Tzardis PJ, et al. Simultaneous pancreas and kidney transplants versus single kidney transplants and previous kidney transplants in uremic patients and single pancreas transplants in nonuremic diabetic patients: comparison of rejection, morbidity, and long-term outcome. Transplant Proc 1990; 22: 622.
13. Gruessner RWG, Dunn DL, Gruessner AC, Matas AJ, Najarian JS, Sutherland DER. Recipient risk factors have an impact on technical failure and patient and graft survival rates in bladder-drained pancreas transplants. Transplantation 1994; 57: 1598.
14. Jordan ML, Shapiro R, Vivas CA, et al. FK 506 rescue for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994; 57: 860.
15. Jindal RM. Posttransplant diabetes mellitus - a review. Transplantation 1994; 58: 1289.
16. Hirano Y, Fujihara S, Ohara K, Katsuki S, Noguchi H. Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation 1992; 53: 889.
17. Tze WJ, Tai J, Murase N, Tzakis A, Starzl TE. Effect of FK506 on glucose metabolism and insulin secretion in normal rats. Transplant Proc 1991; 23: 3158.
18. Rilo HLR, Zeng Y, Alejandro R, Carroll PB, et al. Effect of FK506 on function of human islets of Langerhans. Transplant Proc 1991; 23: 3164.
19. Ericzson BG, Wijnen RMH, Kobota K, Kootstra G, Groth CG. FK-506 induced impairment of glucose metabolism in the primate - studies in pancreatic transplant recipients and in non-transplanted animals. Transplantation 1992; 54: 615.
20. Carroll PB, Boschero AC, Li MY, Tzakis AG, Starzl TE, Atwater I. Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. Transplantation 1991; 51: 275.
21. Steinmüller TM, Haus-Jürgen G, Schleicher J, et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism - a randomized trial. Transplantation 1994; 58: 669.
22. Jindal RM, Popescu I, Schwartz ME, et al. Diabetogenicity of FK 506 versus cyclosporine in liver transplant recipients. Transplantation 1994; 58: 370.
23. Krentz AJ, Dousset B, Mayer D, et al. Metabolic effects of cyclosporine A and FK506 in liver transplant recipients. Diabetes 1993; 42: 1753.
24. Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE. Insulin requirements after liver transplantation and FK-506 immunosuppression. Transplantation 1993; 56: 862.
25. Gunnarsson R, Klintmalm, Lundgren G. Deterioration in glucose metabolism in pancreatic transplant recipients after conversion from azathioprine to cyclosporine. Transplant Proc 1984; 16: 709.
26. Tydén G, Brattstrom C, Gunnarrson R, et al. Metabolic control at two months to 4.5 years after pancreatic transplantation, with special reference to the role of cyclosporine. Transplant Proc 1987; 16: 2294.
27. Robertson RP, Franklin G, Nelson L. Intravenous glucose tolerance and pancreatic islet beta-cell function in patients with multiple sclerosis during 2-year treatment with cyclosporine. Diabetes 1989; 38: 58.
28. Teuscher AU, Seaquist ER, Robertson RP. Diminished insulin secretory reserve in diabetic pancreas transplant and nondiabetic kidney transplant recipients. Diabetes 1994; 43: 593.
29. Demetris AJ, Banner B, Fung J, Shapiro R, Jordan M, Starzl TE. Histopathology of human allograft rejection under FK 506: a comparison with cyclosporine. Transplant Proc 1991; 23: 944.
30. Japanese FK506 Study Group. Morphological characteristics of renal allografts showing renal dysfunction under FK506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK506 nephropathy? Transplant Proc 1993; 25: 624.
31. Moutabarrik A, Ishibashi M, Kameoka H, et al. In vitro FK506 kidney tubular cell toxicity. Transplant Proc 1991; 23: 3137.
32. Tauxe WN, Mochizuki T, McCauley J, Starzl TE, Jain A, Charron M. A comparison of the renal effects (ERPF, GFR, and FF) of FK506 and cyclosporine in patients with liver transplantation. Transplant Proc 1991; 23: 3146.
33. Backman L, Nicar M, Levy M, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Transplantation 1994; 57: 519.
34. Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation. Transplantation 1994; 58: 170.
35. Mueller AR, Platz KP, Bechstein WO, et al. Neurotoxicity after orthotopic liver transplantation. Transplantation 1994; 58: 155.
36. Hadley S, Samore MH, Lewis WD, Jenkins RL, Karchmer AW, Hammer SM. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59: 851.
37. Reyes J, Tzakis AG, Bonet H, et al. Lymphoproliferative disease after intestinal transplantation under primary FK 506 immunosuppression. Transplant Proc 1994; 26: 1426.
38. Cox KL, Lawrence-Miyaskai LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK 506 after liver transplantation. Transplantation 1995; 59: 524.